Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 384 participants.

Also called NCT04026165

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 384 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04026165
  • EudraCT 2018-003951-39
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Japan, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04026165. Randomized; double masking; primary purpose treatment. Start 2019-07-24 (actual); primary completion 2021-09-03 (actual). Results posted on 2022-12-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
Acronym
MOSAIC
Condition
Diabetic Kidney Disease
Intervention (Drug)
SEL
Intervention (Drug)
Placebo
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct04026165
Content hash
e6765804b084dfa079177a006dafe28035f9f8f9323311e33a568e65645d4c4b